# Calcitonin Gene-related Peptide Antibody in Acute Mountain Sickness

> **NCT07653516** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 30 (estimated)

## Conditions studied

- Acute Mountain Sickness

## Interventions

- **DRUG:** Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07653516
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-06-01
- **Primary completion:** 2027-07-31
- **Final completion:** 2027-07-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07653516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07653516, "Calcitonin Gene-related Peptide Antibody in Acute Mountain Sickness". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07653516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*